• Myriocin Workflow for Sphingolipid Research

  2026-09-15

  Use Myriocin to connect SPT activity with ceramide production, apoptosis, cell growth, and pathway remodeling in a controlled experimental workflow. The approach combines dose-response design, orthogonal lipid and phenotype assays, and the SPTLC2-centered cardiovascular mechanism highlighted by recent research.

• GW4064 Workflows for FXR Signaling Research

  2026-09-15

  GW4064 provides a selective, ligand-based way to interrogate FXR activation across lipid metabolism and toxicant-induced liver fibrosis models. This guide connects receptor pharmacology with LX-2 collagen-deposition assays, emphasizing dosing control, pathway-resolved readouts, and stability-aware handling.

• (S)-Mephenytoin in Intestinal Organoid PK

  2026-09-14

  Explore how (S)-Mephenytoin can qualify CYP2C19-linked oxidative metabolism in human iPSC-derived intestinal models. This article translates organoid innovation into practical pharmacokinetic assay decisions, controls, and interpretation limits.

• AO/PI Staining Solution for Reliable Cell Counts

  2026-09-14

  AO/PI Staining Solution (SKU K2269) supports fluorescence-based cell counting by separating membrane-intact and membrane-compromised cells with acridine orange and propidium iodide. This scenario-based guide helps researchers select, optimize, and interpret a fluorescent cell viability assay while avoiding common debris and red blood cell interference.

• Alfuzosin HCl: Assay Workflows & Optimization

  2026-09-13

  Build reproducible Alfuzosin HCl workflows for spectrophotometric quantification, formulation testing, and exposure control in benign prostatic hyperplasia research. Learn how absorbance subtraction and ratio-difference analysis resolve overlapping spectra, plus practical troubleshooting steps for stocks, matrices, and calibration.

• Flavopiridol Beyond Arrest: A Translational Stress Map

  2026-09-12

  Flavopiridol, also known as L868275, is more than a cell cycle arrest agent. This thought-leadership analysis connects pan-CDK pharmacology with ER-stress biology, outlines a validation workflow, and defines how translational researchers can distinguish established evidence from testable hypotheses in cancer research and intestinal stem cell models.

• GR-Dependent Hippocampal CYP Suppression by PCN

  2026-09-11

  This 2025 mouse study identifies a tissue-specific response to pregnenolone 16α-carbonitrile (PCN): CYP3A11 and CYP2B10 increase in liver but decrease in hippocampus. Genetic and pharmacological evidence indicates that glucocorticoid receptor signaling, rather than PXR, mediates the hippocampal CYP suppression and attenuation of phenytoin-associated neurotoxicity.

• Neuromedin S (rat): Practical GPCR Assay Guide

  2026-09-11

  Neuromedin S (rat), SKU B5466, provides a defined peptide agonist for controlled studies of neuromedin U receptor signaling in rat-relevant GPCR/G protein assay systems. This guide covers preparation, storage, controls, and troubleshooting; the reagent is for research use only and should not be used for diagnostic, therapeutic, or clinical purposes.

• Cisplatin Workflows for Cancer Research

  2026-09-10

  Cisplatin (CDDP) supports reproducible DNA-damage, apoptosis, and chemotherapy resistance studies when solvent handling, exposure timing, and matched controls are tightly managed. This workflow connects cell viability and apoptosis assays with a hypothesis-driven gastric cancer stem-cell model based on TAK1–YAP signaling.

• Polygodial Workflows for TRPA1 Channel Research

  2026-09-10

  Build reproducible TRPA1 activation assays with Polygodial, from DMSO stock preparation and acute calcium imaging to epithelial inflammatory readouts. This workflow connects channel-level ion flux with Ca2+/NFAT-associated signaling while emphasizing controls, timing, and interpretation limits.

• n-Dodecyl-β-D-maltoside for WecA Discovery

  2026-09-09

  WecA illustrates why membrane-protein discovery depends on more than expression yield. This thought-leadership article examines how n-Dodecyl-β-D-maltoside can become a strategically controlled variable in WecA purification, functional validation, and translational anti-tuberculosis research.

• UK-5099 Workflows for Mitochondrial Metabolism

  2026-09-09

  UK-5099 enables controlled interrogation of mitochondrial pyruvate entry in cellular, insulinoma, and whole-blood immunometabolism assays. This workflow-focused guide connects MPC inhibition with assay design, matrix-aware controls, and practical troubleshooting.

• Tetrandrine Workflows for Ion Channel Research

  2026-09-08

  Build reproducible Tetrandrine assays for calcium signaling, inflammation, neuroscience, and cancer biology research. This guide combines solvent control, orthogonal readouts, and structure-guided screening logic to distinguish genuine ion-channel effects from formulation or cytotoxicity artifacts.

• CX-5461 in Cervical Cancer and Mitotic Catastrophe

  2026-09-08

  A June 2026 Biochemical Pharmacology study shows that the RNA polymerase I inhibitor CX-5461 suppresses cervical cancer cell growth by coupling DNA damage to aberrant mitotic entry and mitotic catastrophe. The findings also support combining CX-5461 with cisplatin, providing a mechanistic rationale for investigating Pol I inhibition in recurrent or platinum-resistant cervical cancer.

• EZ Cap™ OVA mRNA for Immune Model Workflows

  2026-09-07

  EZ Cap™ OVA mRNA provides a defined, Cap 1–capped Ovalbumin mRNA payload for reproducible expression, immune-response modeling, and delivery comparisons. Its strongest use case is a controlled bridge between gene expression studies and vaccine development research, especially when paired with lower-inflammation lipid delivery systems.

8400 records 1/560 page Next 12345 下5页 Last page